Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.

ABSTRACT:

Background

While current clinically administered anticoagulant medications have demonstrated effectiveness, they have also precipitated significant risks: severe bleeding complications including, but not limited to, gastrointestinal hemorrhaging and intracranial and other life-threatening major bleedings. An ongoing effort is being made to identify the best targets for anticoagulant-targeted drugs. Coagulation factor XIa (FXIa) is emerging as an important target of current anticoagulant treatment.

Objective

This review will summarize the development of anticoagulants and recent advances in clinical trials of experimental factor XI inhibitors from a clinical application perspective.

Results

As of 1 January 2023, our search screening included 33 clinical trials. We summ

SUBMITTER: Xia Y 

PROVIDER: S-EPMC10300994 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature